Envista Holdings Corp. (NYSE: NVST) shares climbed 2.3% in premarket trading on Thursday after JPMorgan upgraded the stock to Overweight from Neutral.
Analyst Lilia-Celine B. Lozada raised the price target to $32 from $29, reflecting expectations that the company’s fundamentals are strengthening. The upgrade comes ahead of Envista’s Investor Day scheduled for September 17, where management is expected to outline a medium-term core growth framework.
The projected growth range is modestly above the prior 2–4% guidance, with estimates pointing to a potential 2.5–4.5% or 3–4% range. Street expectations for 2027 and beyond currently sit near 3.5%, aligning with the company’s updated outlook.
Lozada cited Envista’s improved execution and a more durable organic growth algorithm as key reasons for the upgrade. The analyst also noted that the company’s valuation has not fully reflected its strengthening fundamentals, adding that consistency and quality in the medtech sector have become increasingly scarce.
If management can demonstrate a sustainable mid-single-digit growth profile, Lozada argued, the current valuation would appear even more compelling.
